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ABSTRACT 
 
The current models for equity and access to new oncological treatments are under 
strain due to the economic and demographic crisis in Europe as well as the rising 
costs of innovative drugs. 
Cancer treatment needs a model of patient-centered care in which an interdisciplinary 
care plan, based on evidence-based practice is essential for patient wellbeing. The 
drug review process should distinguish what is real innovation from what is just new. 
The breakthrough of innovation lead to a huge rising of costs all over Europe.  
Accordingly with the Article 64 of the Constitution of the Portuguese Republic 
(CRP), the state has the primary duty of ensuring health protection regardless of their 
economic circumstances. The state has to ensure a rational and efficient nationwide 
coverage in health human resources and facilities and to direct its action towards the 
socialization of the costs of medical care and medicines. 
Physicians should be focused in the doctor-patient relationship and informed consent 
is important especially when new medicines are prescribed (amount of information, 
what information and end of life information) 
Related with informed consent there is therapeutic privilege which can be resumed to 
the retain of information considering the beneficence principle (Portuguese penal 
code 157) 
Also utilitarianism and social justice (Beauchamp, 2009) has to be considered without 
compromising human dignity. The principle of economy cannot be ignored in the 
provision of public services and it implies excellence, clinical governance and 
optimization of social rights through good governance of public and private resources 
allocated to the health system.  
An interdisciplinary approach is essential for the new oncological drugs approval, 
considering several interrelated areas such as human rights, economic opportunities, 
good governance and development. A close relation of all healthcare stakeholders can 
improve policies and operating practices that enhance the competitiveness to catalyze 
social change and/or address economic and social needs. 
The healthcare stakeholders will require a deeper understanding of global oncology 
trends, multidisciplinary decisions will be mandatory and governments will have to 
decide what they will be able to pay in the next years. Transdisciplinary decision 
between civil society, pharmaceuticals, healthcare professionals and policymakers is 
essential in order to assure quality, access to innovation and equity in oncological 
care.  
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ABSTRACT  
The current models for equity and access to new oncological treatments are under strain due 
to the economic and demographic crisis in Europe as well as the rising costs of innovative 
drugs. 
Cancer treatment needs a model of patient-centered care in which an interdisciplinary care 
plan, based on evidence-based practice is essential for patient wellbeing.  
Physicians should be focused in the doctor-patient relationship and informed consent is 
important especially when new medicines are prescribed. 
Related with informed consent there is therapeutic privilege. Moreover, utilitarianism and 
social justice has to be considered without compromising human dignity and the principle of 
economy cannot be ignored in the provision of public services. 
An interdisciplinary approach is essential for the new oncological drugs approval. Therefore, 
transdisciplinary decision between civil society, pharmaceuticals, healthcare professionals 
and policymakers is essential in order to assure quality, access to innovation and equity in 
oncological care.  
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INTRODUCTION 
The multidisciplinary in the treatment of oncological patients is essential for patient wellbeing 
given the nature of their illness and its multimodal treatment. The unmet healthcare needs of 
cancer patients, with potentially harmful repercussions on patients’ health and well-being1, 2 
presents a challenge for the different professionals involved in the treatment. 
The provision of health care is considered a public good and in some countries a right in 
which the government has an important role in funding both basic and clinical research; 
regulating safety and efficacy; determining availability, equity and access; and often pricing 
and/or reimbursement of health products and services.3  
Patients with cancer usually receive care from multiple professionals, working in a variety of 
settings, whose services may be provided either concurrently or at different points in time.4, 5 
Cancer treatment needs a model of patient-centered care in which an interdisciplinary care 
																																								 																				
1 Morrison V et al. Common, important, and unmet needs of cancer outpatients. Eur J Oncol 
Nurs, (2012), 16: 115–123. 
2 Tremblay D et al. Conditions for production of interdisciplinary teamwork outcomes in 
oncology teams: protocol for a realist evaluation. Implementation Science, (2014), 9.1: 76. 
3  OCDE - Biomedicine and health innovation: synthesis report - 2010 
http://www.oecd.org/health/biotech/46925602.pdf (Accessed: 14 Jan 2015). 
4 Howell D et al. A Pan-Canadian Clinical Practice Guideline: Assessment of Psychosocial 
Health Care Needs of the Adult Cancer Patient. Toronto: Canadian Partnership Against 
Cancer (Cancer Journey Action Group) and the Canadian Association of Psychosocial 
Oncology, (2009). http://www.capo.ca/Fatigue_Guideline.pdf. (Accessed: 10 Jan 2015). 
5 Comité des représentants de la population atteinte de cancer et des proches (REPOP): 
Besoins des personnes atteintes de cancer et de leurs proches au Québec, Recommandations, 
Avis, (2005). [http://www.merici.ca/ 
Bibliotheque_pdf/msss_quebec/besoins_pers_cancer.pdf] (Accessed: 2 Feb 2015) 
 
plan, based on evidence-based practice, can be developed with objectives shared by the 
different practitioners on the team.6 
It is increasingly important that the drug review processes reflect not only increased survival 
and quality of life of patients but essentially, to distinguish what is real innovation that is just 
new. This is even more important at each year since the breakthrough of innovation is 
changing the paradigm, especially in oncology where the discovery of new oncological drugs 
lead to a huge rising of costs.7 In Europe, this problem has increased due to the economic 
crisis because funding has decreased and there was also a general trend towards cuts in new 
drugs, with consequent loss for the patients.2 
The OECD has done important work in the development of a comprehensive policy strategy 
to harness innovation for stronger and more sustainable growth and development, and to 
address the key societal challenges of the 21st century such as the growing constraints on 
public health expenditures and funding gaps.3 
The type of government funding is different between the different European countries. In the 
Netherlands, the coverage of health care is universal and guaranteed by the government 
although there is regulation by the private law and there are private insurers to offer a health 
care package. These insurers must accept all individuals and they can choose the insurer.8, 9  
																																								 																				
6 Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical 
literature. Soc Sci Med, (2000), 51:1087–1110.  
7 Price P and Karol S. Treatment of Cancer Sixth Edition. CRC Press, (2014). 
8 Schäfer W. et al. The Netherlands: health system review. Health systems in transition, 
(2010), 12.1: xxvii-1. 
9 Thompson JR. Counterparty risk in financial contracts: Should the insured worry about the 
insurer? Available at SSRN 1278084, (2009). 
 
In Spain the model is universal and free but each of the 17 autonomous regions have a 
Ministry of Health responsible for the financing and delivery of health care. National and 
regional taxes account for about 68% of total health expenditure.9, 10 
Also in Italy the health model is based on cost-free and universal access and is funded by the 
state.9, On the other hand, the French model is based on the contributions of users and 
employers for the National Health Insurance Required. This covers almost the entire 
population but the government focused on the protection of vulnerable groups.9, 11, 12 France 
also uses models of risk sharing in drugs, based on the framework agreement between the 
LEEM (Les Entreprises du Medicament - group of pharmaceutical companies) and the CEPS 
(Committee Economique des Produits De Santé).11  
In the Belgian health model there is a system of compulsory health funds, individuals pay 
taxes according to their income and may freely choose their health fund.13 
In Germany, there is a social insurance that covers about 88% of the population that is 
financed by compulsory contributions. This requirement applies to all employed persons with 
incomes up to € 48,000 / year. Above this value, individuals can choose to continue or not to 
benefit from the health fund.14 
																																								 																				
10 Vogler S et al. Pharmaceutical pricing and reimbursement information (PPRI)–new PPRI 
analysis including Spain. Pharmaceuticals Policy and Law, (2009), 11.3: 213-234. 
11 Vogler S et al. Pharmaceutical policies in European countries in response to the global 
financial crisis. Southern med review, (2011), 4.2: 69. 
12 Latitude iniciativa. Avaliação clínica e económica do medicamento com vista ao seu 
financiamento - Síntese da sessão plenária e recomendações, (2013). 
www.iniciativalatitude.org/ (Accessed 3 Jan 2015). 
13 Gerkens S and Merkur S. Belgium: Health system review. Health Systems in Transition, 
(2010), 12.5: 1–266. 
14 Busse, Reinhard, and Miriam Blümel. Germany. Health system review, (2014). 
The national Swedish health service is free, universal access and state funding but based on 
taxes paid by users.15 
The model most frequently reported health in the literature is the UK, which is a national 
health service based on the principle of a free service to all residents, with the state 
guaranteeing universal access of users to care for via taxes paid by users.15 The National 
Institute for Health and Clinical Excellence (NICE), a special health authority of the national 
health service English (NHS) established in 1999, is a model for the development of clinical 
guidelines and also plays an important role in pioneering technology assessment in health 
systems.16 This institute makes decisions at national level, which may conflict with what is 
(or is believed to be) the best interests of a particular patient. However, process transparency 
and decisions, the logic of those decisions, the opportunity to appeal any decisions and the 
presence of mechanisms to ensure that the other conditions are met make this institute a 
reference in Europe for decisions on approval medicines in oncology. These features are also 
defended by Browman the presentation of the "6-STEPPS tool"17, which is a Canadian 
oncology decision tool with a perspective similar to that of NICE. Another feature of NICE is 
the ability to negotiate the price of new medicines and to set rules for co-payment for new 
pharmaceutical products.15, 18  However, in 2006 the NICE refused cetuximab and 
																																								 																				
15 Kanavos P et al. Differences in costs of and access to pharmaceutical products in the 
European Union. Directorate general for internal policies policy department a: Economic and 
scientific policy, PE 451.481 (2012), 20-25. 
16 Schlander M et al. Budget impact analysis of drugs for ultra-orphan non-oncological 
diseases in Europe. Expert review of pharmacoeconomics & outcomes research, (2015), 1-9. 
17 Browman GP et al. 6-STEPPPs: A modular tool to facilitate clinician participation in fair 
decisions for funding new cancer drugs."Journal of Oncology Practice, 4.1(2008): 2-7. 
18 Espín J et al. Experiences and impact of European risk-sharing schemes focusing on 
oncology medicines. Brussels: Commissioned by the European Commission, Directorate-
General Enterprise, (2011). 
bevacizumab for administration to patients with colon-rectal carcinoma metastatic 
considering that this medicine was too expensive compared to the survival provided to 
patients, which led to severe public criticism. This demonstrates how ethical issues about 
rationing of medicines is a controversial and sensitive issue and demonstrated the need for an 
involvement of civil society in oncological decisions.19 In fact, the criteria for decisions in the 
process should consider internal and external factors. Internal factors to consider are the 
clinical benefit (effectiveness and adverse effects), drug costs, alternative treatments 
available, decisions in other hospitals /systems, the size of the affected population, severity of 
illness and past decisions. External factors that influence the decision-making are the doctors, 
patients, the pharmaceutical industry and independent researchers.20 
All of the above health models are focused on funding issues and cost-effectiveness. A 
change of mentality ("new mindset") to realize that health is necessary, human rights, 
economic opportunities, good governance and development are interrelated areas in a 
complex and interdependent world.21 
In Portugal, accordingly with the Constitution of the Portuguese Republic (article 64), 
everybody has the right to health protection and the primary duty of the State is to ensure the 
right to health protection such as the access for all citizens to medical care, regardless of their 
economic circumstances.22 However, the economic recession associated with population 
																																								 																				
19 Fleck LM. Just Caring: Defining a Basic Benefit Package. J Med Philos, (2011), 36.6: 589-
611.   
20 Vuorenkoski L et al. Decision-making in priority setting for medicines—A review of 
empirical studies. Health Policy, (2008), 86.1: 1-9.  
21 Benatar SR et al. Global health ethics: the rationale for mutual caring. International Affairs, 
79.1 (2003): 107-138. 
22 Rueff, MC. Rationalization in Health: A Legal-Constitutional Perspective. Medicine and 
Law - World Association for Medical Law, (2015), 34.2: 321-334. 
ageing, lead to a decrease in the resources of the state22, 23 which affects several medical areas 
such as the approval of new oncological drugs. The state, in order to ensure that it is still able 
to satisfy the health care requested by citizens, must have enough resources.  
The crisis has caused civil society and the governments that serve them to place renewed 
focus on the social welfare benefits of investment in innovation.3   
The authors intend to analyze the different fundamental bioethical tensions that can arise 
when the cancer patient's health care may be compromised by financial restrictions in the 
National Health Service.  
 
METHODOLOGY 
The researchers used a qualitative methodology (transdisciplinary method) for the analysis of 
the medical-legal content24, 25 where, from a right of autonomous medicine, develop the 
branches representing the segments correspondingly relevant major classical disciplines 
which are civil law, public law and criminal law. The researchers considered the dimensions 
of medical care; economic restrains and clinical governance; human rights; healthcare 
management; corporate social responsibility and corporate social value. This inductive 
methodology, own the right of medicine, is relevant to address the various problems inherent 
to the issues of medical law for the strategic management of hospital cancer therapy because 
it allows a global view and from the inside out of the problem under study.  
 
																																								 																				
23 Garel P and Lombardi G. Hospitals in Europe – data and trends. Hospital Healthcare. Hope 
Bulletin, 020, (2012). 
24 Rueff MC. O segredo médico como garantia da não-discriminação – estudo de caso: VIH-
SIDA. Coimbra editora, (2009), 173-180.  
25 Eser, A. Perspectivas do Direito (Penal) da Medicina. Revista Portuguesa de Ciência 
Criminal, (2004b), 14 (1 e 2): 11-63. 
 
RESULTS AND DISCUSSION 
a) Medical consent and evidence based medicine 
Innovation in cancer account for an increasing proportion of developed-country health 
budgets.26 The increased cancer risk awareness and better access to more effective preventive 
and curative treatments allowed a prolonged survival for cancer patients. However, it is 
essential that patients can be informed about the new medicines and, based on that, to decide 
if they want to do the treatments especially since cancer treatments have a lot of secondary 
effects and can even be life-threatening. Patient autonomy is facilitated by informed consent 
and a physician–patient dialogue educates the patient about the available treatment options, 
their risks and benefits and allows for the creation of a negotiated treatment plan guided by 
the patient's values and goals. Moreover, informed consent include roles and responsibilities 
of patients and providers and will lead providers to prioritize the more self-directed (and self-
protective) goals of describing patient obligations and the consequences of their 
noncompliance and to seek procurement of the patient's signature on the agreement over the 
discussion which lies at the core of the informed consent process.27 
A physician–patient relationship remains dependent upon trust, not contract enforcement.27 
Therefore, informed consent is important when new medicines are prescribed but there are 
questions about: the amount of information; what information; end of life information. 
Related with informed consent there is therapeutic privilege (retaining of information 
																																								 																				
26 Chamberlain C. et al. Does the cancer drugs fund lead to faster uptake of cost-effective 
drugs&quest; A time-trend analysis comparing England and Wales. British journal of cancer, 
(2014), 111.9: 1693-1702.  
27 McGee S. and. Silverman D. Treatment Agreements, Informed Consent, and the Role of 
State Medical Boards in Opioid Prescribing. Pain Medicine, (2015), 16.1: 25-29. 
 
considering the beneficence principle).28  The term "Therapeutic privilege" refers to the 
withholding of information by the clinician during the consent process in the belief that 
disclosure of this information would lead to the harm or suffering of the patient.29 
A legitimate question that arises is whether it is permissible to inform all cancer patients 
about the risks of treatment and prognosis. For example, if the patient is depressed, can this 
information have negative effects that become detrimental to the patient? This question arises 
incidentally contemplated in paragraph 1 " in fine " Article 157 of the Portuguese Criminal 
Code that allows the non-disclosure of information to the patient " if it involves the 
communication of circumstances , to be known by the patient , would endanger his life or 
would be likely to cause serious harm to health, physical or mental” . 
b) Economistic criteria and clinical governance  
The multidisciplinarity in oncology is important to promote the improvement of cancer care 
quality but patients and clinicians may have different ideas about what constitutes a cancer 
care decision27 and the economic European restrictions is forcing a change in healthcare. 
There are controversies considering the restricted access to cancer drugs as an important 
cause to relatively poor survival from cancer in UK.26 However, in spite of the European 
economic crisis,30 health care reforms across all countries in Europe aimed to maintain health 
care quality with lower costs.  
We can analyze the Portuguese paradigm of European recession. Accordingly with the Article 
64 of the Constitution of the Portuguese Republic (CRP), the state has the primary duty of 
																																								 																				
28 Richard C et al. Therapeutic privilege: between the ethics of lying and the practice of truth.. 
Journal of medical ethics, (2010), 36.6: 353-357. 
29  Etchells, Edward, et al. "Bioethics for clinicians: 2. Disclosure." Canadian Medical 
Association Journal, (1996), 155.4: 387-391. 
30 Garel P and Lombardi G. Hospitals in Europe – data and trends. Hospital Healthcare. Hope 
Bulletin, 020. (2012). 
 
ensuring health protection regardless of their economic circumstances. The state has to ensure 
a rational and efficient nationwide coverage in health human resources and facilities and to 
direct its action towards the socialization of the costs of medical care and medicines.22 The 
right to health is a social right, implies legislative measures and is dependent on existing 
economic resources.22, 31  Since Portugal is a country with a high level of legal health 
protection, it requires excellence and hospital governance as a vehicle for clinical quality and 
an instrument of health care excellence.22 As also defended by Canotilho, the doctors 
(including medical oncologists and hematologists, needed to take into account  the economic 
conditions mentioned in the code of ethics and the basic law (principle of economy)  for 
public health in their freedom for prescription.22, 31 
The innovation is increasing and the availability of new drugs all over Europe is also 
growing.32, 33 Moreover, as the effectiveness of treatments increase (as we could recently 
observed with hepatitis C treatment), that restrictions can became a real problem for patients 
and governments.34 
At the moment the restrictions placed by NICE in England National Health Service, did not 
increase cancer death rates probably because there is the Cancer Drugs Fund which provides 
£200 million annually in England for oncological drugs.26 However, the controversy 
																																								 																				
31 Canotilho JG  and Moreira V. Constituição da República Portuguesa Anotada, vol. I, 4th 
edition, (2007), Coimbra Editora, Coimbra. 
32 Berndt ER et al. Decline In Economic Returns From New Drugs Raises Questions About 
Sustaining Innovations. Health Affairs, 34.2 (2015): 245-252. 
33 Schlander M et al. Budget impact analysis of drugs for ultra-orphan non-oncological 
diseases in Europe. Expert review of pharmacoeconomics & outcomes research 0, (2015), 1-
9. 
34 Obach D et al. How to optimize HCV treatment impact on life years saved in resource-
constrained countries. Hepatology, (2015). 
 
surrounding the future of the Cancer Drugs Fund in England is already debated because there 
is a lack of funds.35  
In 2010, was created a Cancer Drugs Fund (CDF) in order to minimize the disparity in 
oncological patients’ access to new drugs in England compared with other countries’.26 The 
CDF was to provide access to drugs not yet appraised by NICE, not licensed or that was not 
considered cost-effective.26 However, the huge raise of innovation imply that from the £200 
million annual CDF, a further £400 million investment will be needed to continue the CDF 
beyond 2014.36 The CDF in England, are assumed to reflect societal preferences for NHS 
resource allocation but a recent study conducted by Linley37 explored, with a survey to 4118 
UK adults, the societal preferences for these and other criteria, including those proposed for 
rewarding new medicines under the future value-based pricing (VBP) system. Respondents 
supported the criteria of innovation with substantial health benefits but did not support several 
issues such as the CDF and the end-of-life premium which rise the question of policies 
introduced on the basis of perceived—and not actual—societal values in the different 
countries may lead to inappropriate resources allocation. 
																																								 																				
35 Smith E and Raftery J. Value Assessments in UK Cancer Care: Measuring Benefit, 
Assessing Cost and Determining Funding. ASCO daily news, (2014). 
http://am.asco.org/value-assessments-uk-cancer-care-measuring-benefit-assessing-cost-
determining-funding (Accessed: 20 Feb 2015). 
36 Cancer Research UK. Government announces extension of Cancer Drugs Fund, Cancer 
News, (2013).  http://www.cancerresearchuk.org/cancer-info/ news/archive/cancernews/2013-
09-28-Government-announces-extensionof-cancer-Drugs-Fund (Accessed: 18 Dec 2014). 
37 Linley WG., and Dyfrig A. Hughes. Societal Views on Nice, Cancer Drugs Fund And 
Value-Based Pricing Criteria For Prioritizing Medicines: A Cross-Sectional Survey Of 4118 
Adults In Great Britain. Health economics, (2013), 22.8: 948-964. 
 
Although cancer will always be a devastating condition with serious physical and emotional 
components for patients and their caregivers, change is clearly necessary to preserve equity of 
access to care to all patients, regardless of their disease. NICE operates within a country and 
political environment where, for some, the notion of a QALY has proved unpalatable, leading 
to a parallel system of drug funding through the Cancer Drugs Fund, which operates 
counterpoint to NICE’s principles. This may benefit patients and the pharmaceutical industry 
in the short term, but is economically unsustainable.35 
In Portugal the health system is funded mostly through transfers from the Government 
budget, meaning general taxation is the main funding source of the National Health Service 
(NHS). The public transfers to the NHS account for 16.1% of the planned Government 
expenditure for 2012.38   
The life quality of the Portuguese population and availability of the health care services has 
improved in the last 50 years with the consequent longer life expectation.39 However, the 
health inequalities, made the current system inefficient. In oncology the main problems are 
the centralization of physicians in the main cities, the lack of alignment in decision making 
for new drugs, the insufficient culture of management performance and accountability in the 
hospitals and the limited information to monitor and drive performance improvements. 
Reflecting on the methodological challenges to the sustainability of the social state maybe we 
can consider Canotilho who believes that the Law continues to be an essential command and 
a reliable tool in our society.40   
																																								 																				
38 Barros PP. Health policy reform in tough times: the case of Portugal. Health Policy, (2012), 
106.1: 17-22. 
39 Appleby J. Spending on health and social care over the next 50 years. The King’s Fund, 
London. Available via http://www. kingsfund. org. uk/time-to-think-
differently/publications/spending-health-and-social-care-over-next-50-years, (2013). 
40 Canotilho, José Joaquim Gomes. Estudos sobre Direitos Fundamenais. 2nd ed., Coimbra 
Editora, (2008), Coimbra. 
c) Human rights 
The right to health is a fundamental right and governments must generate availability of 
health services besides healthy and safe working conditions, adequate food, clothing, housing, 
food and clothing. (Universal declaration of human rights, article 25). 
Changes in society, with the notion of social responsibility, brought the perception that ethical 
behavior is essential in organization’s practices especially in the way they deal with aspects 
such as human rights.41 The concept that health and human rights are both powerful and 
important for human well-being and health workers should consider their responsibilities to 
respect human rights in developing policies, programs and practices, and to contribute 
actively to improve societal realization of rights.42 However, the European economic crisis 
can compromise the right to health since governments do not have money enough in order to 
continue financing national health services.43 The huge technological growth and the amount 
of innovation in oncological and infectious diseases (especially, HIV and HCV) turn this 
situation even more problematic.44  
Considering the example of Portugal, the Constitution of the Portuguese Republic prohibits 
discrimination based on disability and on aggravated health risk (Law 46/2006, of 28 August 
																																								 																																							 																																							 																																							 													
 
41 Brandão C et al. Social responsibility: a new paradigm of hospital governance? Health Care 
Analysis, (2013), 21.4: 390-402. 
42 Mann JM. et al. Health and human rights. Health and human rights, (1994), 6-23. 
43 Cervero-Liceras F et al. The effects of the financial crisis and austerity measures on the 
Spanish health care system: A qualitative analysis of health professionals’ perceptions in the 
region of Valencia." Health Policy, (2015), 119.1: 100-106. 
44 Tabish, SA and Syed N. Future of Healthcare Delivery: Strategies that will reshape the 
Healthcare Industry Landscape. International Journal of Science and Research (IJSR), (2015), 
4.2: 727-758. ISSN (Online): 2319-7064 (Accessed: 3 Mac 2015) 
 
– direct and indirect discrimination) so, with differentiation in drug assessment between 
hospitals, we are infringing a fundamental right. Moreover, the enforcement of Law 46/2006 
implies that every citizen should prevent and mend actions that can result in breach of any 
fundamental right or in denial or infringement of exercise of any economic, social, cultural or 
other, by any person, based on disability.45  
d) Classical utilitarism and social justice or common good an corporate social 
responsibility 
It is essential to consider the classical utilitarism and social justice, in which the physician 
must act so that the consequences are beneficial to the patient and to society.46 The underlying 
ethical utilitarianism is to consider the individual and should be sacrificed for the common 
good of the function.46 Whereas social justice advocated by Beauchamp and Childress, for 
cancer patients, access to new drugs in similar cases, should be comparable and distributed to 
all eligible patients.46 
Considering the problem in Portugal, we find that there is a basic principle which is not 
fulfilled that is the principle of equity.45 In fact, in two different hospitals, even separated by a 
few kilometers, two different patients may not have access to the same drugs. Although 
equity of access to health care is a central objective of many health care systems, this is not 
always possible because socio-economic constraints.47 We could discuss the issue of doctors 
																																								 																				
45 Initial Report of Portugal on the implementation of the Convention on the Rights of 
Persons with Disabilities, (2012). 
(http://cdhps.fpasurdos.pt/ficheiros/files/Relatorio%20inicial%20de%20Portugal%20sobre%2
0a%20implementacao%20da%20CDPD_%2007_08_2012.pdf (Accessed: 29 Nov 2014). 
46 Beauchamp TL and Childress JF. Principals of biomedical ethics. 6th ed. New York: Oxford 
University Press, (2009). 
47 Goddard M and Smith P. Equity of access to health care services: Theory and evidence 
from the UK. Social science & medicine, (2001), 53.9: 1149-1162. 
 
are not all the same and not have the same training and / or update however, the available 
means must be the same and not dependent on hazard. In Portugal, measures are being 
implemented to reduce or even end these arbitrary as the formation of the National 
Commission of Pharmacy and the implementation of SINATS.48 The fear of many clinicians 
and society is that the measures that seem beneficial "ad initium" may be too restrictive and 
prevent the prescription of drugs already approved and marketed in Europe for its clinical 
benefit, which goes against the principle of state social, already debated in countries like 
Germany. German doctrine, recognized by the German Constitutional Court (BVerfG of 
12.06.2005), refers to the right of a “minimum of existence”, as “derived from the rights to 
life, physical integrity, and freedom in general, all in connection with the principle of the 
social state”.22  
e) From corporate social responsibility to corporate social value 
The regulatory agencies (such as the EMEA and FDA), governments, non- governmental 
organizations and patient associations have identified the most efficient route to market for 
health products. Formal network of health professionals help in providing feedback and data 
about health innovation3 such as new drugs in oncology. Cancer is a priority for health 
systems around the world because of three main factors: a) the higher incidence, growing and 
aging populations; b) the impact of patients and caregivers productivity loss; c) and due to 
rising treatment costs.49 It is necessary to find technical and legal solutions to improve 
research and patient’s access to new drugs with a reduced bureaucracy. Moreover, 
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governments should tolerate and encourage experimentation and search for emerging best 
practices even knowing that there is no single model of firm or inter firm organization which 
has emerged as a clear success.3  
Health organizations, especially the ones in public service, have more extensive duties to key 
stakeholder groups such as the employees, communities, customers (patients) and suppliers 
(health care professionals).50 Friedman defended that ‘‘social responsibility of business is to 
maximize profits’’51 which is not the case in public organizations, especially in healthcare.50 
In general, the legitimacy of an organization’s behavior is one of the cornerstones upon which 
its survival and development within society is founded.52 In public healthcare service the 
survival mainly depends on government funds and if it responds to the satisfaction of 
stakeholder demands (specially the main clients). The clients are the patients which represent 
the society.  This kind of stakeholders wants to have accessibility,53 quality and equity.54 The 
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problem is that it is difficult to have all these three characteristics with limited funds since 
health innovation is growing and the costs are rising, especially in oncology.55 “The average 
cost per month of branded oncology drug treatment in the U.S. is now about $10,000, up from 
an average of $5,000 a decade ago” which implies an incremental value considering the 
variability of patient response, the frequent changes to protocol needed for patient care, and 
underlying issues of equity and patient care.49 The American Society of Clinical Oncology 
(ASCO) is committed to improving cancer prevention, diagnosis, and treatment and 
eliminating disparities in cancer. Moreover ASCO considered that pharmaceutical industry 
investment and those paying patient treatments should be guided by evidence-based and cost-
effective practices.56 
CSR has four dimensions which can be visualised has a piramid.: a) In the botton there are the 
economic responsabilities where we can include the production of goods and services to earn 
profit; b) then we have the legal responsabilities because it is essential to obey the law and to 
attain the profits within the confines of the law; c) the third step is the ethical responsabilities 
since it is necessary to be ethical special in medicine; in the top of the pyramid there are the 
discretionary responsibility which is strong related with philantrophy.57  
Therefore, considering the model of Piaggio, it is necessary to define strategic objectives for 
sustainability at the economic, environmental and social levels. To acomplish that 
sustainability plan considering the corporate social responsability it is essential a code of 
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ethics and the colaboration of all stakeholders (customers, employees, trade unions, civil 
society, research institutes, media, public administration sector, pharmaceuticals, politics, 
shareholders and financers).58  
The concept of shared value has emerged from a series of Harvard Business Review (HBR) 
articles written by Porter and Kramer with work focusing explicitly on the nonprofit sector, 
specifically an examination of how foundations can create social value.59 Later, there where 
the idea to create social and economic value, using social programs to enhance the firm’s 
competitive context.60 By 2006, this had developed into a broader analysis of how to integrate 
corporate social responsibility (CSR) into core business strategy, where the term ‘shared 
value’ was coined for the first time.61 “The concept of shared value can be defined as policies 
and operating practices that enhance the competitiveness of a company while simultaneously 
advancing the economic and social conditions in the communities in which it operates”.62 
“Shared value creation focuses on identifying and expanding the connections between 
societal and economic progress”.62 
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The concept of shared value rests on the premise that both economic and social progress must 
be addressed using value principles in which “value is defined as benefits relative to costs…” 
and recognizes that “social harms or weaknesses frequently create internal costs for firms”.62  
It is important in healthcare, namely in oncology to increase efficiency, quality and 
sustainability. Shared value is defining a whole new set of competitive advantages that arise 
from creating shared value and will often be more sustainable than conventional cost because 
quality improvements prevail.62 
The notions of CSR and CSV are strongly related but there are differences between them.63 In 
CSR the value is “doing good”; it is related with citizenship, philanthropy, sustainability; it is 
discretionary or happens in response to external pressure; it is separated from profit 
maximization; the agenda is determined by external reporting and personal preferences; the 
impact is limited by corporate footprint and CSR budget. For another site, in CSV the value is 
economic and consider the societal benefits relative to cost; joint company and community 
value creation; it is integral to competing and to profit maximization; the agenda is company 
specific and internally generated; and realigns the entire company budget. However, in both 
cases, compliance with laws and ethical standards and reducing harm from corporate 
activities are assumed.63 
CONCLUSION 
The healthcare stakeholders will require a deeper understanding of global oncology trends 
(IMS institute for healthcare informatics, 2014), multidisciplinary decisions will be 
mandatory and governments will have to decide what they will be able to pay in the next 
years. This kind of transdisciplinarity between civil society, pharmaceuticals, healthcare 
professionals and policymakers is essential in order to assure quality, access to innovation and 
equity in oncological care. 
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